Institute of Molecular and Translational Medicine

Studie kolektivní imunity (SARS-CoV-2-CZ-Preval-II)

Ústav molekulární a translační medicíny LF UP a Fakultní nemocnice Olomouc zahájí v úterý 18.1.2022 nábor do studie PREVAL 2, zaměřené na stav imunity proti viru SARS CoV 2. Studie se v první fázi mohou zúčastnit jen zájemci, kteří se zúčastnili studie PREVAL 1 v květnu 2020 a zároveň obdrželi zvací SMS zprávu s nabídkou zapojit se. Registrace na preval.zarezervujse.cz

REVIEW: Coronavirus infection: An immunologists' perspective

Coronavirus infections are frequent viral infections in several species. As soon as the severe acute respiratory syndrome (SARS) appeared in the early 2000s, most of the research focused on pulmonary disease. However, disorders in immune response and organ dysfunctions have been documented. Elderly individuals with comorbidities exhibit worse outcomes in all the coronavirus that cause SARS.

A breakthrough method in the research of the proteotoxic stress of cells

Scientists have unveiled a breakthrough method in the research of the proteotoxic stress of cells that leads to neurodegenerative diseases and cancer.

IMTM's director Marián Hajdúch is a member of The Research, Development and Innovation Council

We are pleased to inform you that the director of ÚMTM Marián Hajdúch has become a member of The Research, Development and Innovation Council (R&D&I Council). R&D&I Council is a professional and consultancy body of the Government of the Czech Republic in the field of research, experimental development and innovation.

IMTM WILL BE PART OF THE OF THE CZECH ADVANCED TECHNOLOGY AND RESEARCH INSTITUTE

The Palacký University Academical Senate has approved the Statute of the Czech Advanced Technology and Research Institute of the Palacky University (CATRIN), a new university institute into which university research centers will be integrated.

IMTM DECLARES WAR AGAINST COVID - 19

We confirm that the Laboratory of Experimental Medicine of the Institute of Molecular and Translational Medicine is in the final phase of implementation of high-throughput testing.

MOLECULAR BASIS OF DISEASES AND MOLECULAR TARGET

Research program aims at identification and description of metabolic pathways, signaling pathways, genetic and epigenetic changes causing human diseases, particularly focusing cancer, inflammatory and infectious diseases.

News

Informace o studii kolektivní imunity PREVAL 2

Thursday, January 13, 2022

Information about collective immunity study (SARS-CoV-2-CZ-Preval-II) [ENG + CZ]

Read article

IMTM co-organized successful OL4PERMED conference

Thursday, January 6, 2022

OL4PERMED covered latest topics of pathology, molecular pathology, predictive oncology, and histology as well as COVID-19 section.

Read article

European School of METABOLOMICS 2022

Thursday, January 6, 2022

March, 14th to 18th 2022 — The school for early career scientists

Read article

Digital Genomics Seminar

Thursday, October 21, 2021

26th October, 2021 Room 1.09

Read article

Twitter Follow us

Tweets by IMTM_Olomouc

Featured publications

VAN GOOL, A., F. BIETRIX, E. CALDENHOVEN, K. ZATLOUKAL, A. SCHERER, J. LITTON, G. MEIJER, N. BLOMBERG, A. SMITH, B. MONS, J. HERINGA, W. KOOT, M. SMIT, M. HAJDÚCH, T. RIJNDERS a A.E.

USSI. Bridging the translational innovation gap through good biomarker practice. Nature Reviews. Drug Discovery. 2017, 16(9), 587-588. ISSN 1474-1776 . IF: 57.000. PMID: 28450744

GILLILAND, C.T., D. ZUK, P. KOCIS, M. JOHNSON, S. HAY, M. HAJDÚCH, F. BIETRIX, G. AVERSA, C.P. AUSTIN a A.E.

USSI. Putting translational science on to a global stage. Nature Reviews Drug Discovery. 2016, 15, 217-219. ISSN 1474-1776. IF: 57.000. PMID: 27032820

MAYA-MENDOZA, A., P. MOUDRÝ, J. MERCHUT-MAYA, M. LEE, R. STRAUSS a J. BÁRTEK.

High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018, 559(7713), 279-284. ISSN 0028-0836. IF: 41.577. PMID: 29950726

ŠKROTT, Z., M. MISTRÍK, K. ANDERSEN, S. FRIIS, D. MAJERA, J. GURSKÝ, T. OŽDIAN, J. BARTKOVA, Z. TURI, P. MOUDRÝ, M. KRAUS, M. MEDVEDÍKOVÁ, J. VÁCLAVKOVÁ, P. DŽUBÁK, I. VROBEL, P. POUCKOVA, J. SEDLACEK, A. MIKLOVICOVA, A. KUTT, J. MATTOVA, C. DRIESSEN, Q. DOU, J. OLSEN, M. HAJDÚCH, B. CVEK, R. DESHAIES a J. BÁRTEK.

Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017, 552(7684), 194-199. ISSN 0028-0836. IF: 40.137. PMID: 29211715

XU, G., J. CHAPMAN, I. BRANDSMA, J. YUAN, M. MISTRÍK, P. BOUWMAN, J. BARTKOVA, E. GOGOLA, D. WARMERDAM, M. BAZARAS, J. JASPERS, K. WATANABE, M. PIETERSE, K. KERSBERGEN, W. SOL, P. CELIE, P. SCHOUTEN, B. VAN DEN BROEK, A. SALMAN, M. NIEUWLAND, I. DE RINK, J. DE RONDE, K. JALINK, S. BOULTON, J. CHEN, D. VAN GENT, J. BÁRTEK, J. JONKERS, P. BORST a S. ROTTENBERG.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015, 521(7553), 541-544. ISSN 0028-0836. IF: 38.138. PMID: 25799992

DIETLEIN, F., B. KALB, M. JOKIC, E. NOLL, A. STRONG, L. THARUN, L. OZRETIC, H. KUNSTLINGER, K. KAMBARTEL, W. RANDERATH, C. JUNGST, A. SCHMITT, A. TORGOVNICK, A. RICHTERS, D. RAUH, F. SIEDEK, T. PERSIGEHL, C. MAUCH, J. BARTKOVA, A. BRADLEY, M. SPRICK, A. TRUMPP, R. RAD, D. SAUR, J. BÁRTEK, J. WOLF, R. BUTTNER, R. THOMAS a H. REINHARDT.

A Synergistic Interaction between Chk1-and MK2 Inhibitors in KRAS-Mutant Cancer. Cell. 2015, 162(1), 146-159. ISSN 0092-8674. IF: 28.710. PMID: 26140595

ALL PUBLICATIONS

Studie kolektivní imunity (SARS-CoV-2-CZ-Preval-II)

REVIEW: Coronavirus infection: An immunologists' perspective

A breakthrough method in the research of the proteotoxic stress of cells

IMTM's director Marián Hajdúch is a member of The Research, Development and Innovation Council

IMTM WILL BE PART OF THE OF THE CZECH ADVANCED TECHNOLOGY AND RESEARCH INSTITUTE

IMTM DECLARES WAR AGAINST COVID - 19

MOLECULAR BASIS OF DISEASES AND MOLECULAR TARGET

News

Informace o studii kolektivní imunity PREVAL 2

IMTM co-organized successful OL4PERMED conference

European School of METABOLOMICS 2022

Digital Genomics Seminar

Twitter Follow us

Featured publications

VAN GOOL, A., F. BIETRIX, E. CALDENHOVEN, K. ZATLOUKAL, A. SCHERER, J. LITTON, G. MEIJER, N. BLOMBERG, A. SMITH, B. MONS, J. HERINGA, W. KOOT, M. SMIT, M. HAJDÚCH, T. RIJNDERS a A.E.

GILLILAND, C.T., D. ZUK, P. KOCIS, M. JOHNSON, S. HAY, M. HAJDÚCH, F. BIETRIX, G. AVERSA, C.P. AUSTIN a A.E.

MAYA-MENDOZA, A., P. MOUDRÝ, J. MERCHUT-MAYA, M. LEE, R. STRAUSS a J. BÁRTEK.

Technology & services

Technologies available for licensing

Core facilities

Diagnostics & services

Clinical trials

Featured research projects

Research infrastructures